Emerson Tops Q4 Estimates, Lifts Dividend 7%, Sets FY27 Adjusted EPS Guidance Near $7.25
EMR sits 36% above its 52-week low of $122.635.
Summary
Emerson posted Q4 adjusted EPS of $1.86, up 15%, on 7% sales growth, raised its quarterly dividend 7% to $0.595, and guided FY27 adjusted EPS to about $7.25 with $3.8-3.9 billion of free cash flow.
Key Events · Earnings and Guidance · EMR
-
Q4 Sales and EPS Beat
Q4 net sales came in at $5,201 million, up 7% from $4,855 million, while adjusted EPS of $1.86 rose 15% from $1.62; GAAP EPS was $1.33, up 24%.
-
Orders and Margins Expand
Underlying orders grew 14% in Q4 and 9% for the full year. Q4 pretax margin reached 19.2% versus 15.6% a year earlier, and adjusted segment EBITA margin rose 160 bps to 29.1%.
-
Dividend Raised 7%
The quarterly dividend rises to $0.595 per share, payable December 10, 2026 to stockholders of record November 13, 2026.
-
Initial FY27 Guidance
Management guides FY27 net sales growth of ~5%, adjusted EPS of ~$7.25, operating cash flow of $4.3-4.4 billion and free cash flow of $3.8-3.9 billion.
Analysis · EMR · Manufacturing
Emerson closed fiscal 2026 ahead of expectations, with Q4 sales up 7% to $5.2 billion and adjusted EPS up 15% to $1.86 as underlying orders rose 14% on long-cycle project activity. The board lifted the quarterly dividend 7% to $0.595, and management issued initial FY27 guidance of roughly $7.25 in adjusted EPS alongside $3.8-3.9 billion of free cash flow, enough to fund about $3.8 billion in buybacks and dividends. With the stock near its 52-week high, the bar was already elevated; the guidance framework, rather than the backward-looking quarter, is what sets the next leg of the thesis.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2240 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EMR was trading at $166.40 on NYSE in the Manufacturing sector, with a market capitalization of approximately $92.8B. The 52-week trading range was $122.64 to $171.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.